UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma

Bluemke, E; Bulte, D; Bertrand, A; George, B; Cooke, R; Chu, K-Y; Durrant, L; ... Muirhead, R; + view all (2020) Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma. Clinical and Translational Radiation Oncology , 22 pp. 44-49. 10.1016/j.ctro.2020.03.001. Green open access

[thumbnail of 1-s2.0-S2405630820300148-main.pdf]
Preview
Text
1-s2.0-S2405630820300148-main.pdf - Published Version

Download (1MB) | Preview

Abstract

Background and purpose: Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma. / Materials and methods: T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs. / Results: There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome. / Conclusions: These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.

Type: Article
Title: Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma
Location: Ireland
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ctro.2020.03.001
Publisher version: https://doi.org/10.1002/1873-3468.13125
Language: English
Additional information: Copyright © 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Chemoradiotherapy, Hypoxia, MOLLI T1-Mapping, MRI, Oxygen Enhanced MRI (OE-MRI), Tumour
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10094577
Downloads since deposit
9,348Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item